JPWO2016103904A1 - 超速崩壊錠剤及びその製造方法 - Google Patents
超速崩壊錠剤及びその製造方法 Download PDFInfo
- Publication number
- JPWO2016103904A1 JPWO2016103904A1 JP2016565996A JP2016565996A JPWO2016103904A1 JP WO2016103904 A1 JPWO2016103904 A1 JP WO2016103904A1 JP 2016565996 A JP2016565996 A JP 2016565996A JP 2016565996 A JP2016565996 A JP 2016565996A JP WO2016103904 A1 JPWO2016103904 A1 JP WO2016103904A1
- Authority
- JP
- Japan
- Prior art keywords
- disintegrating tablet
- orally disintegrating
- producing
- tablet
- particle composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 239000003826 tablet Substances 0.000 claims abstract description 56
- 239000006191 orally-disintegrating tablet Substances 0.000 claims abstract description 41
- 239000002245 particle Substances 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000005469 granulation Methods 0.000 claims description 19
- 230000003179 granulation Effects 0.000 claims description 19
- 239000007884 disintegrant Substances 0.000 claims description 17
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 14
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 13
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 11
- 238000005550 wet granulation Methods 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 27
- 238000004108 freeze drying Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 10
- 229940105329 carboxymethylcellulose Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 229960000913 crospovidone Drugs 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229950008138 carmellose Drugs 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- -1 oncology drugs Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100288387 Caenorhabditis elegans lab-1 gene Proteins 0.000 description 1
- 239000004605 External Lubricant Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
[態様1]
比表面積が1.50乃至2.50mm2/mg及び重量が10〜50mgである、口腔内崩壊錠剤。
[態様2]
直径が4mm以下の剤形が隅丸平錠である、態様1記載の口腔内崩壊錠剤。
[態様3]
錠剤硬度が10N〜21Nである、態様1又は2記載の口腔内崩壊錠剤。
[態様4]
水中崩壊時間が7秒以下で、口腔内崩壊時間が5秒以下である、態様1乃至3のいずれか一項に記載の口腔内崩壊錠剤。
[態様5]
酸型カルボキシメチルセルロースからなる第1の崩壊剤成分、結晶セルロースを含み、炭酸水素塩を含まない、態様1乃至4のいずれか一項に記載の口腔内崩壊錠剤。
[態様6]
崩壊性粒子組成物を薬効成分と混合し、得られた混合物を打錠することを含む、態様1乃至5のいずれか一項に記載の口腔内崩壊錠剤の製造方法。
[態様7]
崩壊性粒子組成物を製造するときに湿式造粒工程を含む態様6記載の口腔内崩壊錠剤の製造方法。
[態様8]
崩壊性粒子組成物を製造するときに二段造粒工程を含む、態様6又は7記載の口腔内崩壊錠剤の製造方法。
[態様9]
打錠圧縮力2乃至3kNを加えて打錠する、態様6乃至8のいずれか一項に記載の口腔内崩壊錠剤の製造方法。
[態様10]
態様6乃至9のいずれか一項に記載の口腔内崩壊錠剤の製造方法に用いる、酸型カルボキシメチルセルロースからなる第1の崩壊剤成分を含む崩壊性粒子組成物。
硬度:デジタル木屋式硬度計(KHT-40N、株式会社藤原製作所)を用いて、硬度(N)を測定した。
水中崩壊時間:日本薬局方記載の方法(ただし、補助盤なし)に従い、崩壊試験器(NT−400、富山産業株式会社)を用いて、水中崩壊時間を測定した。ただし、炭酸水素塩含有錠剤については、補助筒を用いた方法で測定した。硬度および崩壊時間はそれぞれ6〜10回の測定を行い、それらの平均値を測定結果とした。
(1)平均粒子径:50〜200ミクロン、(2)水分:0.5〜6重量%。
平均粒子径:崩壊性粒子組成物2gを、φ75mm自動振とう篩器(M−2型、筒井理化学器械株式会社)を用いて測定する。
水分:崩壊性粒子組成物5gをハロゲン水分測定器(HB43型、メトラートレド株式会社)を用いて測定する。
第一湿式造粒工程として、マンニトール(D−マンニトール、メルク株式会社)280g、カルメロース(NS−300、五徳薬品株式会社)75g、結晶セルロース(セオラスPH−101、旭化成ケミカルズ株式会社)100gを流動層造粒機(LAB−1、株式会社パウレック)に投入し、精製水240gを24g/minの速度で噴霧することによって造粒し、さらに、第二湿式造粒工程として、クロスポビドン(ポリプラスドンINF−10、アイエスピー・ジャパン株式会社)40gを添加し、精製水300gを10g/minにて噴霧することによって、造粒物(本発明の崩壊性粒子組成物)を得た。尚、造粒物は以下の物性値を有していた。(1)平均粒子径:93ミクロン、(2)水分:2.3重量%。
得られた造粒物を99.3重量部に、滑沢剤としてステアリン酸マグネシウム(太平化学産業株式会社)0.4重量部、スクラロース(三栄源エフ・エフ・アイ株式会社)0.3部を加え混合し、回転式錠剤機(HT−EX12SS-U、株式会社畑鐵工所)を用い、打錠圧縮力2kN及び3kNにおいて打錠し、直径4.0mm、隅丸平錠、重量17乃至30mgの本発明の実施例1〜5の錠剤を得た。それらの各錠剤における各種の物性値及び特性を以下の表1に示した。
Claims (10)
- 比表面積が1.50乃至2.50mm2/mg及び重量が10〜50mgである、口腔内崩壊錠剤。
- 直径が4mm以下の剤形が隅丸平錠である、請求項1記載の口腔内崩壊錠剤。
- 錠剤硬度が10N〜21Nである、請求項1又は2記載の口腔内崩壊錠剤。
- 水中崩壊時間が7秒以下で、口腔内崩壊時間が5秒以下である、請求項1乃至3のいずれか一項に記載の口腔内崩壊錠剤。
- 酸型カルボキシメチルセルロースからなる第1の崩壊剤成分、結晶セルロースを含み、炭酸水素塩を含まない、請求項1乃至4のいずれか一項に記載の口腔内崩壊錠剤。
- 崩壊性粒子組成物を薬効成分と混合し、得られた混合物を打錠することを含む、請求項1乃至5のいずれか一項に記載の口腔内崩壊錠剤の製造方法。
- 崩壊性粒子組成物を製造するときに湿式造粒工程を含む請求項6記載の口腔内崩壊錠剤の製造方法。
- 崩壊性粒子組成物を製造するときに二段造粒工程を含む、請求項6又は7記載の口腔内崩壊錠剤の製造方法。
- 打錠圧縮力2乃至3kNを加えて打錠する、請求項6乃至8のいずれか一項に記載の口腔内崩壊錠剤の製造方法。
- 請求項6乃至9のいずれか一項に記載の口腔内崩壊錠剤の製造方法に用いる、酸型カルボキシメチルセルロースからなる第1の崩壊剤成分を含む崩壊性粒子組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014261458 | 2014-12-25 | ||
JP2014261458 | 2014-12-25 | ||
PCT/JP2015/080342 WO2016103904A1 (ja) | 2014-12-25 | 2015-10-28 | 超速崩壊錠剤及びその製造方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019074246A Division JP2019131597A (ja) | 2014-12-25 | 2019-04-09 | 超速崩壊錠剤及びその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016103904A1 true JPWO2016103904A1 (ja) | 2017-10-05 |
JP6513702B2 JP6513702B2 (ja) | 2019-05-15 |
Family
ID=56149940
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016565996A Active JP6513702B2 (ja) | 2014-12-25 | 2015-10-28 | 超速崩壊錠剤及びその製造方法 |
JP2019074246A Pending JP2019131597A (ja) | 2014-12-25 | 2019-04-09 | 超速崩壊錠剤及びその製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019074246A Pending JP2019131597A (ja) | 2014-12-25 | 2019-04-09 | 超速崩壊錠剤及びその製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10426732B2 (ja) |
EP (1) | EP3238712B1 (ja) |
JP (2) | JP6513702B2 (ja) |
KR (1) | KR102431738B1 (ja) |
CN (1) | CN106999437A (ja) |
PL (1) | PL3238712T3 (ja) |
TW (1) | TWI731846B (ja) |
WO (1) | WO2016103904A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106999437A (zh) * | 2014-12-25 | 2017-08-01 | 株式会社大赛璐 | 超速崩解片剂及其制备方法 |
EP4096791A1 (en) | 2020-01-31 | 2022-12-07 | Nanocopoeia LLC | Amorphous nilotinib microparticles and uses thereof |
CA3181361A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524650A (ja) * | 2003-04-16 | 2006-11-02 | シントン・ベスローテン・フェンノートシャップ | 口腔内崩壊錠 |
WO2007018192A1 (ja) * | 2005-08-10 | 2007-02-15 | Shionogi & Co., Ltd. | 口腔内崩壊錠剤 |
JP2008540688A (ja) * | 2005-08-01 | 2008-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | チザニジン組成物および前記組成物を使用する治療法 |
WO2013146917A1 (ja) * | 2012-03-29 | 2013-10-03 | 株式会社ダイセル | 酸型カルボキシメチルセルロースを含む崩壊性粒子組成物の製造方法、並びに、該組成物及び該組成物を含む口腔内崩壊錠剤 |
WO2014046035A1 (ja) * | 2012-09-20 | 2014-03-27 | 株式会社ダイセル | 酸型カルボキシメチルセルロース及び結晶セルロースを含む崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤 |
WO2015005241A1 (ja) * | 2013-07-06 | 2015-01-15 | 株式会社ダイセル | 超速崩壊錠剤及びその製造方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4943581B1 (ja) | 1970-08-10 | 1974-11-21 | ||
AU2007203715B2 (en) * | 2006-01-05 | 2012-08-02 | Veloxis Pharmaceuticals A/S | Disintegrating loadable tablets |
JP5366558B2 (ja) * | 2006-12-28 | 2013-12-11 | 武田薬品工業株式会社 | 口腔内崩壊性固形製剤 |
US10548839B2 (en) | 2010-03-16 | 2020-02-04 | Wei Tian | Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form |
JP5656258B2 (ja) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | ガランタミンを含有する口腔内崩壊錠剤 |
KR101418406B1 (ko) * | 2011-08-24 | 2014-07-10 | 한미약품 주식회사 | 실데나필 유리 염기를 포함하는 구강 붕해정 |
CN106999437A (zh) * | 2014-12-25 | 2017-08-01 | 株式会社大赛璐 | 超速崩解片剂及其制备方法 |
-
2015
- 2015-10-28 CN CN201580070751.3A patent/CN106999437A/zh active Pending
- 2015-10-28 KR KR1020177018477A patent/KR102431738B1/ko active IP Right Grant
- 2015-10-28 JP JP2016565996A patent/JP6513702B2/ja active Active
- 2015-10-28 EP EP15872473.2A patent/EP3238712B1/en active Active
- 2015-10-28 PL PL15872473.2T patent/PL3238712T3/pl unknown
- 2015-10-28 US US15/534,955 patent/US10426732B2/en active Active
- 2015-10-28 WO PCT/JP2015/080342 patent/WO2016103904A1/ja active Application Filing
- 2015-12-08 TW TW104141084A patent/TWI731846B/zh active
-
2019
- 2019-04-09 JP JP2019074246A patent/JP2019131597A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524650A (ja) * | 2003-04-16 | 2006-11-02 | シントン・ベスローテン・フェンノートシャップ | 口腔内崩壊錠 |
JP2008540688A (ja) * | 2005-08-01 | 2008-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | チザニジン組成物および前記組成物を使用する治療法 |
WO2007018192A1 (ja) * | 2005-08-10 | 2007-02-15 | Shionogi & Co., Ltd. | 口腔内崩壊錠剤 |
WO2013146917A1 (ja) * | 2012-03-29 | 2013-10-03 | 株式会社ダイセル | 酸型カルボキシメチルセルロースを含む崩壊性粒子組成物の製造方法、並びに、該組成物及び該組成物を含む口腔内崩壊錠剤 |
WO2014046035A1 (ja) * | 2012-09-20 | 2014-03-27 | 株式会社ダイセル | 酸型カルボキシメチルセルロース及び結晶セルロースを含む崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤 |
WO2015005241A1 (ja) * | 2013-07-06 | 2015-01-15 | 株式会社ダイセル | 超速崩壊錠剤及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR102431738B1 (ko) | 2022-08-10 |
EP3238712A1 (en) | 2017-11-01 |
KR20170100544A (ko) | 2017-09-04 |
WO2016103904A1 (ja) | 2016-06-30 |
US20170333352A1 (en) | 2017-11-23 |
EP3238712B1 (en) | 2023-11-01 |
US10426732B2 (en) | 2019-10-01 |
PL3238712T3 (pl) | 2024-04-02 |
TW201636008A (zh) | 2016-10-16 |
CN106999437A (zh) | 2017-08-01 |
JP2019131597A (ja) | 2019-08-08 |
TWI731846B (zh) | 2021-07-01 |
JP6513702B2 (ja) | 2019-05-15 |
EP3238712A4 (en) | 2018-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019131597A (ja) | 超速崩壊錠剤及びその製造方法 | |
JP6479658B2 (ja) | 超速崩壊錠剤及びその製造方法 | |
TW201726113A (zh) | 易服用性固態製劑用粒子組成物及含有該粒子組成物之易服用性固態製劑 | |
JP6469234B2 (ja) | 超速崩壊錠剤及びその製造方法 | |
JP5978335B2 (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
JP2008127320A (ja) | 口腔内速崩壊性固形製剤 | |
WO2015046219A1 (ja) | 崩壊性粒子組成物を含む口腔内崩壊錠剤 | |
JP6151413B2 (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
WO2014171307A1 (ja) | 小児への投与に適した速崩壊錠とその簡便な製造方法 | |
JP5714652B2 (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
JP6853191B2 (ja) | 口腔内保持型崩壊性固形製剤、その製造方法、及び該製造方法に用いる粉体組成物 | |
WO2016060035A1 (ja) | 超速崩壊錠剤 | |
TW201609193A (zh) | 含有碳酸鹽之口腔內崩解錠劑用組成物及口腔內崩解錠劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180618 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180618 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190304 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190319 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190410 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6513702 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |